| BOLT Stock | | | USD 0.58 0.01 1.75% |
VP
Wesley Burwell is VP Resources of Bolt Biotherapeutics
| Address | 900 Chesapeake Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 665 9295 |
| Web | https://www.boltbio.com |
Bolt Biotherapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.2941) % which means that it has lost $0.2941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.5804) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.45 in 2024.
Return On Capital Employed is likely to drop to -0.57 in 2024.
Non Current Liabilities Total is likely to gain to about 46.8
M in 2024, whereas
Total Current Liabilities is likely to drop slightly above 16.1
M in 2024.
Bolt Biotherapeutics currently holds 20.22
M in liabilities with Debt to Equity
(D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Bolt Biotherapeutics has a current ratio of 9.54, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Bolt Biotherapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | VP Age |
| Anita Holz | Milestone Pharmaceuticals | N/A |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. Bolt Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people. Bolt Biotherapeutics (BOLT) is traded on NASDAQ Exchange in USA. It is located in 900 Chesapeake Drive, Redwood City, CA, United States, 94063 and employs 100 people. Bolt Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Bolt Biotherapeutics Leadership Team
Elected by the shareholders, the Bolt Biotherapeutics' board of directors comprises two types of representatives: Bolt Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bolt. The board's role is to monitor Bolt Biotherapeutics' management team and ensure that shareholders' interests are well served. Bolt Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bolt Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randall Schatzman, CEO Director | |
| William Quinn, CFO Secretary | |
| Edith MD, Chief Officer | |
| Michael Alonso, Senior Research | |
| MBA CFA, Chief Officer | |
| Ming Yin, VP Biometrics | |
| Bruce MD, Sr Medicine | |
| Edgar MD, Founder Director | |
| Nathan Ihle, Senior Operations | |
| PharmD BCOP, Senior Development | |
| Wesley Burwell, VP Resources | |
| Karen Bergman, VP Relations | |
| Sarah Nemec, VP Officer | |
Bolt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bolt Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to
measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to
predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.